Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 05 - 20 save search
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
Published: 2021-05-20 (Crawled : 22:00) - biospace.com/
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.35%
H: 2.92%
C: 2.57%
food treatment therapy cancer drug iot nivolumab
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Published: 2021-05-20 (Crawled : 13:00) - prnewswire.com
SEEL | $0.3586 6.1% 180K
|
Health Technology
|
| O: -3.36%
H: 6.96%
C: 4.43%
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 4.24%
H: 5.93%
C: 3.73%
MRKR | $4.06 -0.98% 12K
|
Consumer Services
|
| O: -0.42%
H: 7.14%
C: 5.88%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: -0.2%
H: 0.79%
C: -5.12%
treatment cancer growth pancreatic pancreas
HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO
Published: 2021-05-20 (Crawled : 12:15) - biospace.com/
HOOK | $0.745 -2.6% 280K
|
Health Technology
|
| O: -2.84%
H: 0.54%
C: -9.78%
GILD | News | $66.45 0.44% 4.3M
|
Health Technology
|
| O: 0.23%
H: 1.92%
C: 1.0%
treatment phase 1 cancer phase 3 phase 2
Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis
Published: 2021-05-20 (Crawled : 12:00) - globenewswire.com
OCUP | $1.62 -2.99% 170K
|
Health Technology
|
| O: 1.34%
H: 1.54%
C: -0.22%
treatment potential
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
Published: 2021-05-20 (Crawled : 07:00) - globenewswire.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 8.83%
H: 0.0%
C: -5.52%
treatment results phase 3 linzagolix
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.